Cash from Operations (Quarterly) Chart

View Cash from Operations (Quarterly) for IMNN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (Quarterly) Chart
Start Trial

Historical Cash from Operations (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 -3.026M
March 31, 2026 -3.985M
December 31, 2025 -3.657M
September 30, 2025 -4.441M
June 30, 2025 -2.951M
March 31, 2025 -2.847M
December 31, 2024 -4.421M
September 30, 2024 -4.056M
June 30, 2024 -4.505M
March 31, 2024 -5.874M
December 31, 2023 -3.772M
September 30, 2023 -4.472M
June 30, 2023 -6.692M
March 31, 2023 -4.086M
December 31, 2022 -5.060M
September 30, 2022 -4.685M
June 30, 2022 -5.410M
March 31, 2022 -7.976M
December 31, 2021 -5.088M
September 30, 2021 -3.786M
June 30, 2021 -2.612M
March 31, 2021 -4.737M
December 31, 2020 -3.732M
September 30, 2020 -3.964M
June 30, 2020 -2.948M
Date Value
March 31, 2020 -4.975M
December 31, 2019 -5.617M
September 30, 2019 -4.480M
June 30, 2019 -4.626M
March 31, 2019 -5.536M
December 31, 2018 6.036M
September 30, 2018 -4.266M
June 30, 2018 -4.157M
March 31, 2018 -4.655M
December 31, 2017 -4.209M
September 30, 2017 -5.107M
June 30, 2017 -4.196M
March 31, 2017 -3.13M
December 31, 2016 -4.663M
September 30, 2016 -4.722M
June 30, 2016 -4.250M
March 31, 2016 -4.744M
December 31, 2015 -3.899M
September 30, 2015 -5.321M
June 30, 2015 -5.674M
March 31, 2015 -5.936M
December 31, 2014 -6.510M
September 30, 2014 -5.837M
June 30, 2014 -4.163M
March 31, 2014 -4.844M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Quarterly) Range, Past 5 Years

View Cash from Operations (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Quarterly) Benchmarks

View Cash from Operations (Quarterly) Benchmarks
Start Trial
Phio Pharmaceuticals Corp. -4.035M
Agenus, Inc. -31.20M
Amgen, Inc. 4.002B
Anika Therapeutics, Inc. -0.684M
BioCryst Pharmaceuticals, Inc. 103.98M